Oragenics Inc - Current report filing (8-K)
02 Octubre 2008 - 4:04PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934.
Date
of Report: September 29, 2008
(Date
of earliest event reported)
Oragenics,
Inc
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
FL
|
|
001-38122
|
|
59-3410522
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
Number)
|
|
|
|
13700
Progress Blvd
|
|
32615
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
386-418-4018
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
Name or Former Address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
ITEM
8.01 OTHER EVENTS
Oragenics,
Inc. (d/b/a ONI BioPharma Inc.) announced on September 29, 2008 that it had
entered into a Collaboration Agreement with a major international diagnostics
company regarding ONI’s unique biomarkers for early, middle and late stage
colorectal cancer. The Company recently filed a U.S. patent application covering
the collection of novel proteins and genes that are specifically expressed
in
colorectal cancer.
A
copy of
the September 29, 2008 press release announcing the agreement is attached to
this report as Exhibit 99.1 and is incorporated herein by
reference.
Item
9.01
FINANCIAL
INFORMATION AND EXHIBITS
(c)
Exhibits.
Number
|
Description
|
99.1
|
Press
Release dated September 29, 2008
|
SIGNATURES
In
accordance with the requirements of the Exchange Act, the registrant caused
this
report to be signed on its behalf by the undersigned, thereunto duly authorized
on this 2
nd
day of
October, 2008.
|
ORAGENICS,
INC.
|
|
|
|
|
|
BY:
|
/s/
David B.
Hirsch
|
|
|
David
B. Hirsch
Chief
Financial Officer
|
Oragenics (AMEX:ONI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Oragenics (AMEX:ONI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Oragenics, (American Stock Exchange): 0 recent articles
Más de Oragenics Inc Artículos de Noticias